JAMA
banner
jama.com
JAMA
@jama.com
JAMA is an international peer-reviewed general medical journal and a member of the JAMA Network family of journals.

🌐 JAMA.com
Millions of people are turning to #AI chatbots for mental health support, but is it safe and regulated?

Here’s what experts have to say.
The Rise of Therapy Chatbots
This Medical News article discusses the growing use of generative artificial intelligence chatbots as sources of mental health support.
jamanetwork.com
January 9, 2026 at 5:03 PM
@who.int issued its first guideline on #GLP-1 medications for #obesity.

Here’s what to know about the recommendations.

ja.ma/4py5FfE

#MedSky
6 Takeaways from the WHO’s First Obesity Drug Guideline
This Medical News article discusses key learnings from new World Health Organization guidance on the use of glucagon-like peptide-1 (GLP-1) medications for the treatment of obesity in adults.
ja.ma
January 9, 2026 at 4:35 PM
📊 Research Summary: Early treatment with levosimendan was not associated with improved timing of ECMO weaning, lower mortality, or shorter ICU stay for adults with severe cardiogenic shock supported by #VAECMO.

ja.ma/49N3vny
January 9, 2026 at 2:00 PM
From 2012 to 2023, the proportion of first-time treatment admissions involving methamphetamine injection, with or without opioids, more than doubled, even as overall admissions declined.

ja.ma/3LE5XUb
January 9, 2026 at 12:00 PM
Viewpoint: Although #neurodivergence is often seen as a barrier, research and personal accounts indicate that neurodivergent individuals can possess unique skills beneficial to clinical and scientific work.

ja.ma/49sU7nN
January 8, 2026 at 5:45 PM
Prostatitis involves infection, inflammation, or pain in the prostate gland and affects about 9% of men during their lifetime.

📄 This JAMA Patient Page describes the types of prostatitis and its risk factors, diagnosis, and treatment.

ja.ma/45Gj9yw
January 8, 2026 at 5:30 PM
Kendra D. Sims, PhD, postdoctoral associate in epidemiology, Boston University, discusses Tipping Point Analysis: Assessing the Potential Impact of Missing Data with JAMA Statistical Editor Roger J. Lewis, MD, PhD. ja.ma/3MUGztN
January 8, 2026 at 5:15 PM
Stillbirth affects approximately 5.7 per 1000 births in the US and can occur antenatally (83%) or intrapartum (17%).

💡 This JAMA Insights focuses on #stillbirth, including causes, risk factors, and #prenatal preventive care.

ja.ma/4qLr3il
January 8, 2026 at 5:00 PM
#RSVpreF vaccination during late #pregnancy was not associated with increased risk of preterm birth or hypertensive disorders in interim safety analysis.

ja.ma/3LjUV6w
January 8, 2026 at 4:45 PM
📊 Research Summary: Adding acetaminophen (paracetamol) or hydromorphone to ibuprofen did not improve pain relief for children with acute limb injuries; hydromorphone led to more adverse events.

ja.ma/3NyOFbv
January 8, 2026 at 4:35 PM
💬 Editorial: Randomized clinical trials by Ali et al found no incremental benefit of hydromorphone over ibuprofen for acute musculoskeletal pain in children and adolescents and highlighted higher rates of adverse events with opioid use.

ja.ma/49wLRmQ
January 8, 2026 at 4:25 PM
For children with acute nonoperative limb injuries, pain scores did not improve with addition of either acetaminophen (paracetamol) or hydromorphone to ibuprofen; adverse events were higher with hydromorphone.

ja.ma/4srfxKR
January 8, 2026 at 4:15 PM
Is taking acid-suppressive medications during #pregnancy linked to neuropsychiatric disorders in children?

A large South Korean cohort study published in JAMA found no increased risk in sibling-control analyses, suggesting no causal association.

🔗 Read the full study: ja.ma/3Yv3TRo
January 8, 2026 at 3:14 PM
💬 Viewpoint: Combination-only approvals for new #HIV drugs limit generic substitution and sustain high antiretroviral prices, even after key patents expire.

ja.ma/4jw2Dqz
January 8, 2026 at 3:00 PM
💬 Editorial: The LEVOECMO RCT found no benefit of levosimendan in increasing the rate of successful VA-ECMO weaning or improving mortality compared with placebo; risk of ventricular arrhythmias was greater with levosimendan.

ja.ma/3YtV1eQ
January 8, 2026 at 2:00 PM
RCT: Among patients with severe but potentially reversible cardiogenic shock, early administration of levosimendan did not significantly shorten time to successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning.

ja.ma/4qJzD1c
January 8, 2026 at 1:00 PM
💬 Viewpoint: Implementing subscription-based pricing models for lenacapavir may facilitate broader #PrEP access and contribute to efforts to end the #HIV epidemic.

ja.ma/4q3Vmkl
January 7, 2026 at 5:00 PM
Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide.

This Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.

ja.ma/4pFdlNf
January 7, 2026 at 4:45 PM
Sibling comparisons are a method used in observational studies to address confounding by shared familial factors such as genetics, early-life environment, and socioeconomic status.

📊 Learn more in this JAMA Guide to Statistics and Methods:
ja.ma/4jojGuQ
January 7, 2026 at 4:30 PM
Prenatal exposure to acid-suppressive medication, including proton pump inhibitors and histamine 2 receptor antagonists, was not associated with increased risk of #ADHD, #ASD, or other neuropsychiatric disorders in children.

ja.ma/495WQVn
January 7, 2026 at 4:15 PM
Questions about vaccine safety or ingredients may emerge during routine pediatric visits.

Clinicians can address these concerns by explaining vaccine safety monitoring and proactively offering reliable information.

ja.ma/3NzRSri
January 7, 2026 at 3:45 PM
What is the most important thing to recognize when communicating with families about vaccines?

Author Sean O’Leary, MD, MPH, joined JAMA Senior Editor Anne Cappola, MD, ScM, to discuss evidence-based approaches for discussions with parents about vaccines. ja.ma/4jufUzS
January 7, 2026 at 3:31 PM
📊 Research Summary: Sacubitril/valsartan lowered NT-proBNP more than enalapril, but did not offer significant advantages in clinical outcomes for patients with HF due to #Chagas disease. Both drugs were tolerated similarly.

ja.ma/3LnczpK
January 7, 2026 at 2:00 PM
💬 Editorial: In patients with Chagas cardiomyopathy and heart failure, PARACHUTE-HF trial results demonstrated that sacubitril/valsartan did not reduce major clinical events compared with enalapril.

ja.ma/4syAyDm
January 7, 2026 at 1:00 PM
RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.

ja.ma/4aNRXBs
January 7, 2026 at 12:00 PM